Zinc Acetate Hydrate Supplementation versus Polaprezinc Supplementation for Improving Hypozincemia in Hemodialysis Patients: A Randomized Clinical Trial

Figure 1

Patient selection and randomization. Serum zinc levels are measured in 327 patients on maintenance HD who undergo HD sessions more than thrice weekly in one of the three facilities. Of the 327 patients, 224 patients with zinc levels ≥60 μg/dL were excluded. Of the 103 patients with zinc levels <60 μg/dL, 28 patients were excluded due to lack of eligibility based on the exclusion criteria. The remaining 75 HD patients are allocated to the zinc acetate hydrate (ZAH) group or the polaprezinc (PPZ) group in a 1 : 1 randomization ratio. We finally allocated 37 and 38 patients to the ZAH and PPZ groups.